Pioglitazone add-on therapy in patients with type 2 diabetes effective and safe option for better glycemic control: Study
South Korea: Adjunctive pioglitazone therapy in type 2 diabetes mellitus (T2DM) inadequately controlled with dapagliflozin and metformin yielded considerable metabolic benefits, glycemic improvement, and a low hypoglycemia risk, a phase 3 trial showed. The findings were published online in Diabetes, Obesity and Metabolism on February 29, 2024. The researchers, however, suggest weighing its advantages against […]